Pharmacyclics Announces $21 Billion Acquisition by AbbVie

Firm News

The Wall Street Journal and The New York Times DealBook reported that Olshan client Pharmacyclics announced it was being acquired by Abbvie for $261.25 per share in a combination of cash and stock with a total transaction value of approximately $21 billion. Olshan served as special counsel to Pharmacyclics on certain issues relating to the transaction. 

Media Contact

Marketing Contact
Mizi Mehaj
Marketing & Administrative Manager

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.